Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Adult Vaccines Market - By Product Type, By End Users/Application, and By Region - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 - 2026

Published by Zion Market Research Product code 956482
Published Content info 100 Pages
Delivery time: 2-3 business days
Price
Back to Top
Adult Vaccines Market - By Product Type, By End Users/Application, and By Region - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 - 2026
Published: June 15, 2020 Content info: 100 Pages
Description

Title:
Adult Vaccines Market - By Product Type (Influenza, Zoster, Shingles, Meningococcal, Pneumococcal, MMR, DTP, Hepatitis, and Miscellaneous), By End Users/Application (Healthcare Firms and Hospital), and By Region - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 - 2026.

The global Adult Vaccines Market is projected to record the CAGR of about 7.6% over the period from 2020 to 2026. The report offers assessment and analysis of the Adult Vaccines market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, sales estimates, opportunities, evolving trends, and industry-validated data. The report offers historical data from 2017 to 2019 along with a forecast from 2020 to 2026 based on revenue (USD Million).

Introduction

Vaccination is of huge significance for public health as they help in improving the body immunity. Apart from this, vaccination is the main mode to prevent ailments in infants as well as children and adults for avoiding mortality and illness. Furthermore, eradication of deadly diseases can be prevented successfully through vaccination. Vaccination is an important part of public health programs globally.

According to NCBI, every year vaccine-preventable ailments cause the death of many adults in countries like the U.S. Moreover, as per CDC, adults need a vaccine for influenza each year as the vaccine is this flu vaccine is necessary for persons suffering from chronic illness, elder persons, and pregnant women. As per CDC recommendations each adult must be inoculated with Tdap (Tetanus, Diphtheria, and Pertussis) vaccine once for getting protection against whooping cough if the adult did not get inoculated. Apparently, Td (tetanus, diphtheria) booster inoculation is provided every 10 years for adult. Additionally, pregnant ladies are recommended to get vaccinated through Tdap vaccine during time of pregnancy each time during 27 to 36 weeks of pregnancy.

Furthermore, CDC also recommends HPV vaccine for adults aged between 19 to 26 years that helps in offering them protection against various kinds of human papillomaviruses causing anal & cervical cancers as well as against genital warts if not vaccinated in early teens. Furthermore, adults more than 50 years of age are recommended shingles vaccination, pneumococcal polysaccharide vaccine that offers protection against meningitis & other blood infections, and pneumococcal conjugate vaccine offering protection against pneumonia and pneumococcal ailment. As per NCBI, adult vaccination is also recommended for zoster, measles, hepatitis A, rubella, mumps, hepatitis B, and Haemophilus influenza B.

Market Growth Dynamics

Growing occurrence of contagious ailments in adults along with rise in the initiatives taken by the government supporting vaccine development for adults will boost the market trends. Additionally, growing associations of the government with pharma & biopharma firms for developing novel vaccines will favorably leverage the growth of adult vaccines industry in the years ahead.

Furthermore, breakthroughs in the biomedical domain is anticipated to offer new growth avenues for the global adult vaccines industry over the years ahead. In addition to this rise in the new product launches along with mergers & partnerships between manufacturing firms & government will pave a way for the growth of adult machines industry over the ensuing years.

North America To Account Humunguously Towards Global Market Growth By 2026

The regional market growth over the forecast period is owing to massive occurrence of contagious ailments among the adults in the countries like the U.S. Apart from this, rise in the government funding as well as non-government firms for developing vaccines for adults will embellish the market growth in the sub-continent over the next couple of years.

Key players profiled in the report include are BioCSL (Seqirus), Sanofi Pasteur, Pfizer, Merck, GlaxoSmithKline, Novartis, and Protein Sciences.

The global adult vaccines market is segmented as follows:

  • By product type
  • Pneumococcal
  • Meningococcal
  • MMR
  • Influenza
  • Zoster
  • Shingles
  • Hepatitis
  • DTP
  • Miscellaneous
  • By end-users/application
  • Healthcare Firms
  • Hospital
  • By Region
  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
Table of Contents

Table Of Contents

Chapter 1. Preface

  • 1.1. Report Description and Scope
  • 1.2. Research Scope
  • 1.3. Research Methodulogy
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodulogy

Chapter 2. Executive Summary

  • 2.1. Adult Vaccines Market, 2016–2026(USD Million)
  • 2.2. Adult Vaccines Market: Snapshot

Chapter 3. Global Adult Vaccines Market– Industry Analysis

  • 3.1. Adult Vaccines Market: Market Dynamics
  • 3.2. Market Drivers
    • 3.2.1. Rise in cases of infectious diseases in the adults
    • 3.2.2. Increase in government funding for research activities to develop vaccines
  • 3.3. Porter’s Five Forces Analysis
  • 3.4. Market Attractiveness Analysis
    • 3.4.1. Market attractiveness analysis By End Users/Application
    • 3.4.2. Market attractiveness analysis By Product Type

Chapter 4. Global Adult Vaccines Market– Competitive Landscape

  • 4.1. Company market share analysis
    • 4.1.1. Global Orthopedic Implants Market: company market share, 2019
  • 4.2. Strategic development
    • 4.2.1. Acquisitions & mergers
    • 4.2.2. New Product launches
    • 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
    • 4.2.4. Research and development and Regional expansion
  • 4.3. Price trend analysis

Chapter 5. Global Adult Vaccines Market– End Users/Application Analysis

  • 5.1. Global Adult Vaccines Market overview: By End Users/Application
    • 5.1.1. Global Adult Vaccines Market Share, By End Users/Application,2019 and 2026
  • 5.2. Healthcare Firms
    • 5.2.1. Global Adult Vaccines Market by Healthcare Firms , 2016–2026(USD Million)
  • 5.3. Hospital
    • 5.3.1. Global Adult Vaccines Market by Hospital, 2016–2026(USD Million)

Chapter 6. Global Adult Vaccines Market– Product Type Analysis

  • 6.1. Global Adult Vaccines Market overview: By Product Type
    • 6.1.1. Global Adult Vaccines Market Share, By Product Type, 2019 and 2026
  • 6.2. Influenza
    • 6.2.1. Global Adult Vaccines Market by Influenza, 2016–2026(USD Million)
  • 6.3. Zoster
    • 6.3.1. Global Adult Vaccines Market by Zoster, 2016–2026(USD Million)
  • 6.4. Shingles
    • 6.4.1. Global Adult Vaccines Market by Shingles, 2016–2026(USD Million)
  • 6.5. Meningococcal
    • 6.5.1. Global Adult Vaccines Market by Meningococcal, 2016–2026(USD Million)
  • 6.6. Pneumococcal
    • 6.6.1. Global Adult Vaccines Market by Pneumococcal, 2016–2026(USD Million)
  • 6.7. MMR
    • 6.7.1. Global Adult Vaccines Market by MMR, 2016–2026(USD Million)
  • 6.8. DTP
    • 6.8.1. Global Adult Vaccines Market by DTP, 2016–2026(USD Million)
  • 6.9. Hepatitis
    • 6.9.1. Global Adult Vaccines Market by Hepatitis, 2016–2026(USD Million)
  • 6.10. Miscellaneous
    • 6.10.1. Global Adult Vaccines Market by Miscellaneous, 2016–2026(USD Million)

Chapter 7. Company Profiles

  • 7.1. Sanofi Pasteur
    • 7.1.1. Overview
    • 7.1.2. Financials
    • 7.1.3. Product Portfulio
    • 7.1.4. Business Strategy
    • 7.1.5. Recent Developments
  • 7.2. GlaxoSmithKline
    • 7.2.1. Overview
    • 7.2.2. Financials
    • 7.2.3. Product Portfulio
    • 7.2.4. Business Strategy
    • 7.2.5. Recent Developments
  • 7.3. Novartis
    • 7.3.1. Overview
    • 7.3.2. Financials
    • 7.3.3. Product Portfulio
    • 7.3.4. Business Strategy
    • 7.3.5. Recent Developments
  • 7.4. Merck
    • 7.4.1. Overview
    • 7.4.2. Financials
    • 7.4.3. Product Portfulio
    • 7.4.4. Business Strategy
    • 7.4.5. Recent Developments
  • 7.5. BioCSL (Seqirus)
    • 7.5.1. Overview
    • 7.5.2. Financials
    • 7.5.3. Product Portfulio
    • 7.5.4. Business Strategy
    • 7.5.5. Recent Development
  • 7.6. Pfizer
    • 7.6.1. Overview
    • 7.6.2. Financials
    • 7.6.3. Product Portfulio
    • 7.6.4. Business Strategy
    • 7.6.5. Recent Development
  • 7.7. Protein Sciences
    • 7.7.1. Overview
    • 7.7.2. Financials
    • 7.7.3. Product Portfulio
    • 7.7.4. Business Strategy
    • 7.7.5. Recent Development
Back to Top